Evidence map›Paper›PMID 32064053›Full record

ArticleOncotarget2020

Correction: The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin.

Xinyue Zhang, Jie Yao, Kai Guo, Hu Huang, Siyuan Huai, Rui Ye, Baolong Niu, Tiannan Ji, Weidong Han, Jianxiong Li

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Non-coding RNAs underlying chemoresistance in gastric cancer.Cellular oncology (Dordrecht, Netherlands) · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Xinyue Zhang *Department of Radiotherapy, Chinese PLA General Hospital, Beijing 100853, P.R. China.
Jie Yao *Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, P.R. China.
Kai Guo *Department of Gastroenterology, The 161th Hospital of PLA, Wuhan 430010, P.R. China.
Hu Huang *Department of Oncology, The 161th Hospital of PLA, Wuhan 430010, P.R. China.
Siyuan HuaiDepartment of Radiotherapy, Chinese PLA General Hospital, Beijing 100853, P.R. China.
Rui YeDepartment of Radiotherapy, Chinese PLA General Hospital, Beijing 100853, P.R. China.
Baolong NiuDepartment of Radiotherapy, Chinese PLA General Hospital, Beijing 100853, P.R. China.
Tiannan JiDepartment of Radiotherapy, Chinese PLA General Hospital, Beijing 100853, P.R. China.
Weidong HanDepartment of Molecular Biology, Institute of Basic Medicine, School of Life Sciences, Chinese PLA General Hospital, Beijing 100853, P.R. China.
Jianxiong LiDepartment of Radiotherapy, Hainan Branch of Chinese PLA General Hospital, Sanya 572000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.18632/oncotarget.23249.].

Identifiers

PMID32064053
PMCPMC6996912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.